Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development
Reference number: GID-TA10555
Expected publication date: TBC
The Topic Selection Oversight Panel (TSOP) have determined that cangliflozin would be best assessed and included in the chronic kidney disease and Type 2 diabetes in adults: management update. Therefore the appraisal has been suspended from the Technology Appraisal work programme.